JPWO2019198101A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019198101A5 JPWO2019198101A5 JP2020555466A JP2020555466A JPWO2019198101A5 JP WO2019198101 A5 JPWO2019198101 A5 JP WO2019198101A5 JP 2020555466 A JP2020555466 A JP 2020555466A JP 2020555466 A JP2020555466 A JP 2020555466A JP WO2019198101 A5 JPWO2019198101 A5 JP WO2019198101A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- preparation according
- sugar
- item
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 125000000185 sucrose group Chemical group 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201841013647 | 2018-04-10 | ||
| IN201841013647 | 2018-04-10 | ||
| PCT/IN2019/050293 WO2019198101A1 (en) | 2018-04-10 | 2019-04-10 | Stable formulations of therapeutic antibody |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021521171A JP2021521171A (ja) | 2021-08-26 |
| JP2021521171A5 JP2021521171A5 (https=) | 2022-04-15 |
| JPWO2019198101A5 true JPWO2019198101A5 (https=) | 2022-04-15 |
Family
ID=68164106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020555466A Pending JP2021521171A (ja) | 2018-04-10 | 2019-04-10 | 治療用抗体の安定な製剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12433947B2 (https=) |
| EP (1) | EP3773696A4 (https=) |
| JP (1) | JP2021521171A (https=) |
| CN (1) | CN112292146A (https=) |
| AU (1) | AU2019251453A1 (https=) |
| BR (1) | BR112020020703A2 (https=) |
| CO (1) | CO2020013571A2 (https=) |
| SG (1) | SG11202009876TA (https=) |
| WO (1) | WO2019198101A1 (https=) |
| ZA (1) | ZA202006264B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018007520A (es) | 2015-12-18 | 2018-08-01 | Astellas Pharma Inc | Composicion farmaceutica que comprende un anticuerpo receptor de linfopoyetina estromal timica antihumano. |
| AU2019251452A1 (en) * | 2018-04-10 | 2020-11-26 | Dr. Reddy's Laboratories Limited | Stable antibody formulation |
| WO2024098180A1 (en) * | 2022-11-07 | 2024-05-16 | Wuxi Biologics (Hong Kong) Limited | Pharmaceutical compositions comprising anti-human tslp receptor antibodies and methods of using the same |
| US20240101679A1 (en) * | 2020-12-09 | 2024-03-28 | Dr. Reddy’S Laboratories Limited | Stable aqueous buffer free formulation of an integrin antibody |
| US20240254237A1 (en) * | 2021-06-04 | 2024-08-01 | Polpharma Biologics S.A. | Vedolizumab formulation |
| EP4717712A2 (en) * | 2021-12-27 | 2026-04-01 | Polpharma Biologics S.A. | Vedolizumab formulation |
| KR20250120995A (ko) | 2022-11-07 | 2025-08-11 | 업스트림 바이오, 인크. | 항-인간 tslp 수용체 항체를 포함하는 약제학적 조성물 및 이를 사용하는 방법 |
| WO2024249568A1 (en) | 2023-05-30 | 2024-12-05 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| CN121889424A (zh) | 2023-08-14 | 2026-04-17 | 派拉冈医疗公司 | α4β7整联蛋白结合蛋白及使用方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2358763C2 (ru) | 2003-02-10 | 2009-06-20 | Элан Фармасьютикалз, Инк. | Композиции иммуноглобулина и способ их получения |
| EP2170390B1 (en) * | 2007-06-14 | 2018-11-07 | Biogen MA Inc. | Natalizumab antibody formulations |
| US20090208492A1 (en) * | 2007-06-14 | 2009-08-20 | Elan Pharmaceuticals, Inc. | Lyophilized Immunoglobulin Formulations and Methods of Preparation |
| KR101247418B1 (ko) * | 2007-12-21 | 2013-03-25 | 에프. 호프만-라 로슈 아게 | 항체 제형 |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| DK3311834T3 (da) | 2011-05-02 | 2026-04-20 | Millennium Pharmaceuticals Inc | Formulering til anti-alfa4beta7-antistof |
| WO2017015198A1 (en) | 2015-07-17 | 2017-01-26 | Coherus Biosciences, Inc. | Stable aqeous formulations of natalizumab |
| US20220267449A1 (en) | 2019-06-10 | 2022-08-25 | Takeda Pharmaceutical Company Limited | METHODS OF PRODUCING AN ANTI-a4B7 ANTIBODY |
-
2019
- 2019-04-10 AU AU2019251453A patent/AU2019251453A1/en not_active Abandoned
- 2019-04-10 SG SG11202009876TA patent/SG11202009876TA/en unknown
- 2019-04-10 US US17/045,406 patent/US12433947B2/en active Active
- 2019-04-10 WO PCT/IN2019/050293 patent/WO2019198101A1/en not_active Ceased
- 2019-04-10 EP EP19785714.7A patent/EP3773696A4/en active Pending
- 2019-04-10 BR BR112020020703-9A patent/BR112020020703A2/pt not_active IP Right Cessation
- 2019-04-10 JP JP2020555466A patent/JP2021521171A/ja active Pending
- 2019-04-10 CN CN201980038006.9A patent/CN112292146A/zh active Pending
-
2020
- 2020-10-08 ZA ZA2020/06264A patent/ZA202006264B/en unknown
- 2020-10-28 CO CONC2020/0013571A patent/CO2020013571A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021521171A5 (https=) | ||
| Skehel et al. | Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin | |
| JP2021521159A5 (https=) | ||
| JP2024099682A5 (https=) | ||
| US10736840B2 (en) | Thermally stable vaccine formulations and microneedles | |
| JPWO2019198101A5 (https=) | ||
| Colman | New antivirals and drug resistance | |
| HRP20251316T1 (hr) | Stabilne formulacije polipeptida i njihova upotreba | |
| JP2019536761A5 (https=) | ||
| HRP20131196T1 (hr) | Stabilne formulacije proteina | |
| HRP20250830T1 (hr) | Farmaceutski pripravak s niskim ph koji sadrži konstrukte protutijela koja djeluju na t-stanice | |
| US7048924B2 (en) | Combination antiviral and interleukin-2 therapy for HIV infection | |
| RU2484847C2 (ru) | Лиофилизированный препарат, содержащий гриппозную вакцину, и способ его получения | |
| US20190083402A1 (en) | Process for lyophilized pharmaceutical formulation of a therapeutic protein | |
| JP2010511665A5 (https=) | ||
| JP2019512012A5 (https=) | ||
| JP2019509311A5 (https=) | ||
| JP2017516847A5 (https=) | ||
| JP2017516848A5 (https=) | ||
| JPWO2019198100A5 (https=) | ||
| US9198965B2 (en) | Peptide adjuvant for influenza vaccination | |
| US11376306B2 (en) | Peptides and uses therefor as antiviral agents | |
| JPWO2020206320A5 (https=) | ||
| Whittington et al. | Anti-infectives Recent developments in the antiviral therapy of influenza | |
| Moreno et al. | Didanosine enteric-coated capsule: current role in patients with HIV-1 infection |